Skip to content
PeptideAgent

Press release. For immediate release, . No embargo.

57% of unapproved peptides tracked by PeptideAgent have no randomized human trial, first State of Peptides report finds

PeptideAgent today published State of Peptides, 2026 Q3, an open report on the regulatory status, evidence, prices, adverse event reports, and state access rules for 82 peptides, with every figure downloadable as CSV under CC BY 4.0.

Headline statistics

  • 57% of the 47 tracked peptides without an FDA approval have no randomized human trial behind them (27 peptides).
  • 35 of 82 tracked peptides are FDA approved. The most common status among the rest is "unscheduled" (17 peptides).
  • 51% of tracked peptides are prohibited in sport under the WADA list in force (42 of 82).
  • 12 dated regulatory actions on tracked peptides in 2026 so far, 7 of them in the third quarter.
  • 34 of 94 price channels in our cost data have a dated public source and a published price, covering 12 peptides.
  • 12,083 to 98,396 sum of per-drug FAERS report counts for the FDA-approved GLP-1 and incretin peptides, 2016 versus 2025 (a report naming two of these drugs counts twice). Report counts are not incidence rates.
  • 17 of 50 states allow asynchronous telehealth prescribing; 5 do not, and in 28 the state rules we checked do not address it.

About the report

State of Peptides, 2026 Q3 is built from PeptideAgent's open dataset, where every peptide status, evidence grade, price, and state rule cites a primary source. It covers 82 peptides, 12 dated regulatory actions in 2026, 34 dated price channels, FDA adverse event report counts for 35 FDA-approved peptides, and telehealth and compounding rules in 50 states. Search demand and a consumer survey are listed as in preparation until licensed data is available; no figures are estimated in their place.

Method in brief

  • Regulatory, WADA, and evidence figures are counts over the peptide records, each sourced on its page.
  • The price index includes only channels with a dated public source and a published price.
  • Adverse event counts come from the public openFDA API, pulled on 2026-09-22, with every query URL published. They are counts of reports, not incidence rates, and a report does not show that a product caused an event.
  • State figures come from 50 state records citing each state's own statute or board rule.

The full method, sources, and caveats are in the report.

Data and charts

All charts can be embedded with attribution, and the data is free to reuse under CC BY 4.0 with credit to PeptideAgent and a link to the report.

  • United States regulatory status of tracked peptides: embed from https://peptideagent.ai/embed/report/regulatory-status
  • WADA status of tracked peptides: embed from https://peptideagent.ai/embed/report/wada-status
  • Evidence grade by peptide cluster: embed from https://peptideagent.ai/embed/report/evidence-by-cluster
  • Published monthly cash prices by channel: embed from https://peptideagent.ai/embed/report/price-index
  • FAERS reports per year naming a GLP-1 or incretin peptide: embed from https://peptideagent.ai/embed/report/faers-glp1-trend
  • Asynchronous telehealth prescribing by state: embed from https://peptideagent.ai/embed/report/state-async-map

About PeptideAgent

PeptideAgent is an editorial reference on peptides: evidence grades, United States regulatory status, WADA status, and access, each cited to primary sources. It is not a clinic, pharmacy, or vendor and does not give medical advice.

Media contact

press@peptideagent.ai. We can provide custom cuts of the data and answer questions on method.